Type
|
Public |
---|---|
Traded as | NASDAQ: ANAC |
Industry | Pharmaceutical |
Fate | Acquired by Pfizer |
Key people
|
Paul L. Berns (CEO) |
Website | anacor.com |
Anacor Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It is based in Palo Alto, California, United States. Anacor was founded in 2002 based on technology created by Lucy Shapiro at Stanford University and Stephen Benkovic at Pennsylvania State University. Cofounder David Perry served as CEO and President from 2002 to 2014, and took the company public in 2010. Since then, the company has generated a pipeline of both topical and systemic boron-based compounds of which five are currently in clinical development.
In May 2016, Pfizer announced it would acquire Anacor Pharmaceuticals for $5.2 billion, expanding the company's portfolio in both inflammation and immunology drugs areas.
Boron is a naturally occurring element in the environment, but relative to carbon, hydrogen, nitrogen and oxygen, little research has been done on the role of boron in therapeutics because of the limited understanding of the physical properties necessary to provide boron-based compounds with the attributes required of pharmaceutical therapies as well as difficulty in chemical synthesis. However, boron has two qualities that give it advantages in the small-molecule drug discovery process. First, boron has a unique geometry that allows compounds made from it to have two distinct shapes, giving boron-based drugs the ability to interact with biological targets in novel ways and to address targets not amenable to intervention by traditional carbon-based compounds. And second, boron's enhanced reactivity as compared to carbon allows the molecules to hit targets that are difficult to inhibit with carbon chemistry.
Tavaborole is a topical antifungal drug for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Anacor began its Phase 3 trials in December 2010. Tavaborole inhibits an essential fungal enzyme, leucyl-transfer RNA synthetase, or LeuRS, required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the fungal infection. No treatment-related systemic side effects have been observed in any of its clinical trials. It gained FDA approval in July 2014.
Crisaborole Topical Ointment 2% is a topical anti-inflammatory product for the treatment of psoriasis and atopic dermatitis. Crisaborole Topical Ointment 2% inhibits PDE4 and reduces the production of TNF-alpha, a precursor of the inflammation associated with psoriasis as well as other cytokines, including IL-12 and IL-23, which are proteins believed to be involved in the inflammation process and immune responses. Crisaborole Topical Ointment 2% is currently in Phase 2b for psoriasis and Phase 3 for atopic dermatitis.
2016-05-18 | Downgrade | Mizuho | Buy to Neutral | $98.00 to $99.25 |
2016-05-16 | Reiterated Rating | Jefferies Group | Buy | |
2016-05-16 | Downgrade | Wedbush | Outperform to Neutral | $148.00 to $99.25 |
2016-05-10 | Reiterated Rating | Mizuho | Buy | $95.00 |
2016-05-10 | Reiterated Rating | Cowen and Company | Buy | |
2016-05-10 | Reiterated Rating | Wedbush | Outperform | $148.00 |
2016-05-02 | Reiterated Rating | Wedbush | Outperform | $152.00 to $148.00 |
2016-04-21 | Reiterated Rating | Jefferies Group | Buy | $105.00 |
2016-04-17 | Reiterated Rating | Cowen and Company | Buy | |
2016-03-31 | Reiterated Rating | Mizuho | Buy | $102.00 |
2016-03-23 | Reiterated Rating | Mizuho | Outperform | $103.00 to $102.00 |
2016-03-11 | Reiterated Rating | Wedbush | Outperform | $152.00 |
2016-03-11 | Initiated Coverage | Mizuho | Buy | $103.00 |
2016-03-10 | Reiterated Rating | Jefferies Group | Buy | $105.00 |
2016-03-01 | Reiterated Rating | Cowen and Company | Outperform | |
2016-03-01 | Reiterated Rating | Jefferies Group | Buy | $105.00 |
2016-02-26 | Reiterated Rating | Wedbush | Outperform | $190.00 |
2016-02-24 | Reiterated Rating | Cowen and Company | Outperform | |
2016-01-15 | Reiterated Rating | Wedbush | Outperform | $190.00 |
2016-01-07 | Reiterated Rating | Wedbush | Outperform | $190.00 |
2015-12-28 | Reiterated Rating | Wedbush | Outperform | $190.00 |
2015-12-18 | Reiterated Rating | Wedbush | Outperform | $190.00 |
2015-12-04 | Reiterated Rating | Wedbush | Outperform | $190.00 |
2015-10-22 | Reiterated Rating | Jefferies Group | Buy | $171.00 |
2015-09-09 | Initiated Coverage | JMP Securities | Outperform | $173.00 |
2015-07-21 | Upgrade | Bank of America | Neutral to Buy | |
2015-07-21 | Upgrade | Goldman Sachs | Neutral to Buy | $195.00 |
2015-07-21 | Upgrade | Bank of America Corp. | Neutral to Buy | |
2015-07-21 | Upgrade | Goldman Sachs Group Inc. | Neutral to Buy | $195.00 |
2015-07-14 | Boost Price Target | Jefferies Group | Buy | $80.00 to $171.00 |
2015-07-01 | Boost Price Target | Jefferies Group | Buy | $70.00 to $80.00 |
2015-06-30 | Boost Price Target | Wedbush | Outperform | $72.00 to $85.00 |
2015-05-04 | Boost Price Target | Jefferies Group | Buy | $57.00 to $70.00 |
2015-04-21 | Boost Price Target | Wedbush | Buy | $72.00 |
2015-03-13 | Boost Price Target | Jefferies Group | Buy | $41.00 to $57.00 |
2015-03-13 | Boost Price Target | Wedbush | Outperform | $50.00 to $60.00 |
2015-02-16 | Reiterated Rating | Wedbush | Outperform | $50.00 |
2015-02-03 | Boost Price Target | Wedbush | $50.00 | |
2015-01-26 | Boost Price Target | Jefferies Group | Buy | $34.00 to $41.00 |
2014-12-17 | Initiated Coverage | Goldman Sachs | Neutral | $36.00 |
2014-09-09 | Initiated Coverage | Avondale Partners | Outperform | |
2014-08-08 | Boost Price Target | Jefferies Group | Buy | $24.00 to $25.00 |
2014-05-15 | Reiterated Rating | Jefferies Group | Buy | $24.00 |
2014-05-07 | Reiterated Rating | Jefferies Group | Buy | $24.00 |
2014-04-29 | Reiterated Rating | Jefferies Group | Buy | $24.00 |
2014-04-21 | Initiated Coverage | Jefferies Group | Buy | $24.00 |
2013-10-29 | Boost Price Target | Canaccord Genuity | Buy | $17.00 to $24.00 |
2013-10-21 | Boost Price Target | Canaccord Genuity | Buy | $13.00 to $17.00 |
2013-10-18 | Boost Price Target | Wedbush | $20.00 to $29.00 | |
2013-10-18 | Boost Price Target | Deutsche Bank | Buy | $11.00 to $20.00 |
2013-01-30 | Reiterated | Canaccord Genuity | Buy | $9 to $5 |
2016-05-18 | Downgrade | Mizuho | Buy to Neutral | $98.00 to $99.25 |
2016-05-16 | Reiterated Rating | Jefferies Group | Buy | |
2016-05-16 | Downgrade | Wedbush | Outperform to Neutral | $148.00 to $99.25 |
2016-05-10 | Reiterated Rating | Mizuho | Buy | $95.00 |
2016-05-10 | Reiterated Rating | Cowen and Company | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ANAC 51 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
GLAZER CAPITAL, LLC | 3.15M |
OZ MANAGEMENT LP | 1.40M |
Marshall Wace LLP | 1.04M |
D. E. Shaw & Co., Inc. | 1.02M |
Hudson Bay Capital Management LP | 0.98M |
FIR TREE INC. | 0.88M |
Polar Securities Inc. | 0.82M |
Radcliffe Capital Management, L.P. | 0.82M |
Saba Capital Management, L.P. | 0.79M |
NOMURA HOLDINGS INC | 0.76M |
HBK INVESTMENTS L P | 0.74M |
HSBC HOLDINGS PLC | 0.71M |
ADAGE CAPITAL PARTNERS GP LLC | 0.60M |
UBS OCONNOR LLC | 0.55M |
Davidson Kempner Capital Management LP | 0.50M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
VENROCK ASSOCIATES V LP | 8.87% (3725535) | ANAC / CERU / CSLT / FATE / RCPT / ZLTQ / |
VENROCK ASSOCIATES IV L P | 8.51% (3575535) | AKAO / ANAC / |
PERRY DAVID P President and CEO | 0.86% (361306) | ANAC / |
RHO VENTURES IV LP | 0.58% (243815) | ANAC / IL / |
Parker Geoffrey M. Senior Vice President and CFO | 0.41% (173000) | ANAC / CCXI / GHDX / PRGO / SNSS / |
Chanda Sanjay VP, Int. Head of Drug Dev. | 0.07% (29087) | ANAC / |
Plattner Jacob j Senior VP, Research | 0.04% (17840) | ANAC / |
Maples Kirk R SVP, Program Management | 0.02% (7220) | ANAC / |
Rodriguez Carmen R Snr VP Reg Afrs & Qual. Assur. | 0.02% (7020) | ANAC / |